Understanding genetic variants in lung cancer to improve treatment options
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm
['FUNDING_R01'] · VANDERBILT UNIVERSITY MEDICAL CENTER · NIH-10610721
This study is looking at specific genetic changes in lung cancer patients to see how they might affect treatment options, with the hope of finding better ways to target therapies for each individual.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (NASHVILLE, UNITED STATES) |
| Trial ID | NIH-10610721 on ClinicalTrials.gov |
What this research studies
This research focuses on identifying and characterizing genetic variants of uncertain significance (VUS) in lung cancer patients, particularly novel variants of the EGFR gene. By using a personalized structural biology approach, the study aims to understand how these genetic changes affect tumor behavior and response to targeted therapies. Patients' tumor samples will be analyzed to uncover new insights into these variants, which could lead to more effective treatment strategies. The goal is to enhance precision medicine by determining which genetic alterations can be targeted with specific inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients who have undergone tumor genotyping and have identified variants of uncertain significance.
Not a fit: Patients without lung cancer or those whose tumors do not exhibit variants of uncertain significance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for lung cancer patients based on their unique genetic profiles.
How similar studies have performed: Previous research has shown promise in characterizing genetic variants in cancer, suggesting that this approach could yield significant insights and advancements in treatment.
Where this research is happening
NASHVILLE, UNITED STATES
- VANDERBILT UNIVERSITY MEDICAL CENTER — NASHVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOVLY, CHRISTINE M. — VANDERBILT UNIVERSITY MEDICAL CENTER
- Study coordinator: LOVLY, CHRISTINE M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Disease